

This article was downloaded by:

On: 23 January 2011

Access details: *Access Details: Free Access*

Publisher *Taylor & Francis*

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



Journal of Coordination Chemistry

Publication details, including instructions for authors and subscription information:

<http://www.informaworld.com/smpp/title~content=t713455674>

Synthesis and Characterization of a Series of Water Soluble Amidomalonato-(1R,2R-Cyclohexanediamine)Platinum(II) Complexes

Abdolhossen Talebian^a; Dennis Bensely^a; Dianna Green^b; Philip S. Schein^{bc}

^a Department of Chemistry, Georgetown University, Washington, DC, USA ^b School of Medicine, Vincent T. Lombardi Cancer Research Center, Georgetown University, Washington, DC, USA ^c US Bioscience, Blue Bell, PA, USA

To cite this Article Talebian, Abdolhossen, Bensely, Dennis, Green, Dianna and Schein, Philip S. (1990) 'Synthesis and Characterization of a Series of Water Soluble Amidomalonato-(1R,2R-Cyclohexanediamine)Platinum(II) Complexes', *Journal of Coordination Chemistry*, 22: 3, 165 – 173

To link to this Article: DOI: 10.1080/00958979009408212

URL: <http://dx.doi.org/10.1080/00958979009408212>

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: <http://www.informaworld.com/terms-and-conditions-of-access.pdf>

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

SYNTHESIS AND CHARACTERIZATION OF A SERIES OF WATER SOLUBLE AMIDOMALONATO- (1R,2R-CYCLOHEXANEDIAMINE)PLATINUM(II) COMPLEXES

ABDOLHOSEN TALEBIAN,* DENNIS BENSELY

Department of Chemistry, Georgetown University, Washington, DC 20057, U.S.A.

DIANNA GREEN and PHILIP S. SCHEIN**

Vincent T. Lombardi Cancer Research Center, Georgetown University, School of Medicine,
Washington, DC 20007, U.S.A.

(Received January 11, 1990)

A new series of water soluble platinum(II) complexes of the type $[\text{Pt}(\text{DACH})[\text{R}-\text{CH}(\text{COO})_2]]$, wherein DACH represents 1R,2R-cyclohexanediamine and R represents formamido, acetamido, (penta-O-acetylgluconyl)amino, and gluconylamino have been synthesized. The modes of binding of amidodicarboxylic acid derivatives in these complexes have been determined by various spectroscopic techniques: ^1H , ^{13}C , and $^{195}\text{PtNMR}$; 2D-COSY $\{^1\text{H}-^1\text{H}\}$ and 2D-HETCOSY $\{^1\text{H}-^{13}\text{C}\}$ NMR, MS(FAB), IR and conductivity measurements.

Keywords: Platinum(II) complexes, diamine, bioactivity, NMR, IR

INTRODUCTION


Cis-dichlorodiammineplatinum(II) (*cis*-DDP) is one of the most widely used anti-cancer drugs, either alone or in combination with chemotherapy.¹⁻³ However, its clinical applications are compromised by its dose limiting nephrotoxicity, nausea and vomiting, ototoxicity, neurotoxicity, and myelotoxicity.^{4,5}

Investigators have attempted to develop new platinum complexes with a broader spectrum of antitumor activity, improved therapeutic indices, lower toxic side effects, and in particular, higher water solubility than *cis*-DDP. Numerous new platinum derivatives of the form *cis*-PtA₂X₂, wherein A₂ represents two monodentate or one bidentate amine ligand and X₂ represents two monodentate or one bidentate anionic ligand, have been synthesized and evaluated in preclinical animal studies.⁶⁻⁹ Although most of the second generation platinum complexes are less nephrotoxic than the parent cisplatin, myelosuppression remains an important dose-limiting toxicity.

In an effort to reduce both nephrotoxicity and myelotoxicity, we have synthesized a new series of platinum(II) complexes of the general formula I.

*Author for correspondence

**Present address: US Bioscience, Blue Bell, PA 19422, U.S.A.



- | | |
|-----------------------|---------------------------|
| 1) <i>R,R</i> -FMP | R = H |
| 2) <i>R,R</i> -AMP | R = CH ₃ |
| 3) <i>R,R</i> -AG-AMP | R = H(CHOAc) ₅ |
| 4) <i>R,R</i> -G-AMP | R = H(CHOH) ₅ |

Structure I contains 1*R*,2*R*-cyclohexanediamine (*R,R*-DACH) as its non-leaving group. In preclinical systems, DACH-platinum complexes have received special attention because of their lack of cross-resistance with *cis*-DDP and lower nephrotoxicity.¹⁰ The anionic leaving group in structure I is a substituted malonic acid. Dicarboxylic acid ligand leaving groups that can form a five or six member ring chelation to platinum are the most chemically stable platinum complexes.¹¹ We report here the synthesis and characterization of four such complexes, *cis*-(acetamidomalonato-*O,O'*)(1*R*,2*R*-cyclohexanediamine-*N,N'*)platinum(II) (*R,R*-AMP, 1), *cis*-(formamidomalonato-*O,O'*)(1*R*,2*R*-cyclohexanediamine-*N,N'*)platinum(II) (*R,R*-FMP, 2), *cis*-[(penta-*O*-acetylgluconyl)aminomalonato-*O,O'*](1*R*,2*R*-cyclohexanediamine-*N,N'*)platinum(II), (*R,R*-AG-AMP, 3), and *cis*-(gluconylaminomalonato-*O,O'*)(1*R*,2*R*-cyclohexanediamine-*N,N'*)platinum(II), (*R,R*-G-AMP, 4).

EXPERIMENTAL

Measurements

Melting (decomposition) points, uncorrected, were determined on a Gallenkamp MF-370 instrument. IR spectra were run as KBr pellets on a Nicolet-FT 170SX spectrometer. The 64.52 MHz ¹⁹⁵Pt, 75.46 MHz ¹³C, and 300.13 MHz ¹H nmr spectra were run on a Bruker AM-300 WB spectrometer using a 10 mm tunable probe (a 5 mm probe for ¹H, and ¹³C). An internal lock on the deuterium solvent, D₂O, DMF-*d*₇, and/or DMSO-*d*₆ was used. Except for ¹H, other nuclei were proton-decoupled. The ¹⁹⁵Pt spectra were obtained operating at a spectral width of 50,000 Hz, pulse width of 4 μs, acquisition time of 0.082 ms, and 15,000 to 50,000 scans. Chemical shifts are reported in ppm units, and are relative to internal tetramethylsilane (TMS) for DMF-*d*₇ and DMSO-*d*₆, and sodium 3-(trimethylsilyl)propionate-2,2,3,3-*d*₄ (Tier salt) for D₂O, and to a separate sample of Na₂PtCl₆ (0.5 g in 3 cm³ of D₂O) for ¹⁹⁵Pt. HPLC assays were carried out with a Waters 6000 high-pressure liquid chromatograph operating at 230 nm using a Waters Microbond pack C₁₈ column (3.9 × 300 mm) and a mobile phase (isocratic elution) of 5 mM hexanesulfonic acid sodium salt at a flow rate of 1.5 cm³/min. Molar conductivities were determined using an Amber Science model 4603 solution analyzer. Elemental analyses were performed by Galbraith Laboratories, Knoxville, Tennessee.

Materials

K_2PtCl_4 was purchased from Strem Chemicals (Newburyport, MA); 1*R*,2*R*-cyclohexanediamine (*R,R*-DACH) was obtained from Alfa Chemicals (Danvers, MA) and used as received. Diethylacetamido-, diethylformamido-, and diethylaminomalonate were purchased from Aldrich (Milwaukee, WI). All solvents are reagent grade and were used without further purification.

SYNTHESES

Preparation of dicarboxylic acid ligands.

Amino-, acetamido-, and formamidomalonic acids were prepared by reacting the corresponding diethyl malonate with 0.1 M barium hydroxide in methanol at room temperature for 2 to 6 hr, and then with 1 M sulfuric acid.

Aminomalonic Acid: crystalline white solid; mp 130–131 (foaming); yield 82%; IR 3550–2357 (carboxylic OH), 1706 (carboxylic C=O), 1606 (C=O of COO⁻), 1378, 1228, 1109, 900.

Acetamidomalonic Acid: crystalline white solid; mp 132–133 (dec.); yield 88%, IR 3369 (amide NH), 3500–2300 (carboxylic OH), 1735 (carboxylic C=O) 1713 (amide C=O), 1533 (amide NH overtone), 1227 (carboxylic C–O).

Formamidomalonic Acid: crystalline white solid; mp 116–118 (dec.); yield 86%; IR 3386 (amide NH), 3500–2300 (carboxylic OH), 1760 (carboxylic C=O), 1696 (amide C=O), 1527 (amide NH overtone), 1307, 1181.

(Penta-*O*-acetylgluconyl)aminopropanedioic acid was prepared by reacting a solution of 7.2 g aminomalonic acid (0.060 mol) with 8.6 g of penta-*O*-acetylgluconyl chloride (0.020 mol) in the presence of diisopropylethylamine in a mixture of water and acetonitrile. After the reaction mixture was stirred for 3 hr at room temperature, the acetonitrile was removed under reduced pressure and the water solution was made basic with a saturated solution of sodium bicarbonate. This basic solution was washed with chloroform. The aqueous layer was then made acidic using 3.0 M HCl and extracted with ethyl acetate. The ethyl acetate layer was dried over anhydrous sodium sulfate, filtered, and evaporated to dryness under reduced pressure to give 8.0 g of pure (penta-*O*-acetylgluconyl)aminopropanedioic acid (79% yield). IR 3402 (amide NH), 3704–2450 (carboxylic OH), 1750 (carboxylic and acetyl C=O), 1531 (amide NH overtone), 1218 (carboxylic C–O).

Preparation of gluconylaminopropanedioic acid

To a solution of 11.5 g (0.0227 mol) of (penta-*O*-acetylgluconyl)aminopropanedioic acid in 102 cm³ of a 1:2 water-methanol mixture were added 34 cm³ of triethylamine. The resultant mixture was stirred under a positive nitrogen atmosphere at room temperature for 24 hr. The solvent mixture was then removed and the residue was redissolved in 20 cm³ of water and treated with Amberlite IR-120(H⁺). After removal of the resin, the solution was evaporated to dryness to give the deacetylated product as a white foam (5.6 g, 83% yield). IR 3420–3391 (alcoholic OH and amide NH), 3500–2337 (carboxylic OH), 1729 (carboxylic C=O), 1637 (amide C=O), 1531 (amide NH overtone), 1225 (carboxylic C–O).

Preparation of Complexes

*General Procedure for the Synthesis of cis-(Amidomalonato-O,O') (1*R*,2*R*-cyclo-*

hexanediamine-*N,N'*)platinum(II), complexes 1–3, and *cis*-(2-gluconylaminomalonato-O,O') (1*R*,2*R*-cyclohexanediamine-*N,N'*)platinum(II), 4

To a freshly prepared solution of K_2PtCl_4 was added an equimolar amount of 1*R*,2*R*-cyclohexanediamine in distilled water. The mixture was reacted at room temperature under a nitrogen atmosphere protected from light for 8 hr. The resultant yellow precipitate was then washed successively with 10% HCl, H_2O , ethanol, acetone, and ether. After drying *in vacuo* over P_2O_5 overnight, the *cis*-dichloro(1*R*,2*R*-cyclohexanediamine-*N,N'*)platinum(II) was stirred with an equimolar amount of silver sulfate in distilled, degassed water under a nitrogen atmosphere for 24 hr in the dark. Silver chloride precipitate was removed by filtration and the filtrate was freeze dried to give faintly yellow *cis*-sulfato-DAC-platinum(II) in 90% yield. Addition of *cis*-sulfato-DAC-platinum(II) to a stoichiometric amount of barium 2-(gluconylamino)malonate (prepared *in situ*) resulted in the immediate precipitation of $BaSO_4$. The mixture was stirred at room temperature under nitrogen for 2 hr in the dark, filtered, and the filtrate was concentrated to about 2 cm^3 . Addition of acetone or ethanol to this concentrated solution resulted in the precipitation of the platinum complex. The white platinum solid (4) was successively washed with ethanol, acetone and ether and dried *in vacuo* over P_2O_5 . Decomposition point 182°C ; IR 3100–3300 (NH), 2929 and 2858 (CH, CH_2), 1672 (amide C=O), 1651 (coordinated carboxyl C=O), 1388 (C–O). ^1H NMR (DMF- d_7): δ 8.04(d, 1H, $-(C=O)NH$, $J_{NH-CH} = 7.31$ Hz), 6.38 (dd, 2H, NH_2), 6.15 (bs, 1H, OH), 5.76 (d, 1H, CH, $J_{NH-CH} = 7.31$ Hz), 5.62 (m, 2H, NH_2), 5.03 (bs, 1H, OH), 4.79 (bs, 1H, OH), 4.66 (bs, 1H, OH), 4.53 (bs, 1H, OH), 3.5–4.4 (several overlapping m, 6H, sugar), 2.63 (bs, 2H, $H_1 + H_2$), [2.20 (ud, 2H) and 1.61 (m, 2H), ($H_3 + H_6$)], [1.70 (ud, 2H) and 1.31 (m, 2H), ($H_4 + H_5$)]. ^{13}C NMR (DMF- d_7): δ 172.10, 171.54, 171.18 (carboxylates and amide (C=O)), 73.61, 71.84, 71.46, 70.53 and 63.72 (sugar), 62.50 (C_2), 62.20 (C_1), 58.62 (C_2), 31.49 ($C_3 + C_6$), 23.95 ($C_4 + C_5$). *Anal.*; Calc. for $C_{15}H_{27}N_3O_{10}Pt \cdot 2H_2O$: C, 28.13; H, 4.88; N, 6.56%. Found: C, 28.38; H, 5.00; N, 6.47%.

Preparation of R,R-AMP, 1

R,R-AMP was prepared in the same manner as described above and was recrystallized from DMF- ether in 70% yield. Decomp. point 246°C ; IR 3200–3240 (NH), 2931, 2853 (CH, CH_2), 1617 (amide CO), 1645 (coordinated carboxyl C=O), 1400 (C–O). ^1H NMR (DMSO- d_6): δ 7.65 (d, 1H, $-(C=O)NH$, $J_{NH-CH} = 8.18$ Hz), 6.03 (dd, 2H, NH_2), 5.57 (d, 1H, CH, $J_{NH-CH} = 8.18$ Hz), 5.38 (dist. t, 2H, NH_2), 2.08 (bs, 2H, $H_1 + H_2$), [1.82 (bd, 2H) and 1.20 (m, 2H), ($H_3 + H_6$)], [1.45 (bd, 2H) and 1.02 (m, 2H), ($H_4 + H_5$)]. ^{13}C NMR (D_2O): δ 176.73 and 176.48 (amido and carboxylate (C=O)), 65.56 (C_2), 65.41 (C_1), 61.84 (C_2), 34.57 and 34.49 ($C_3 + C_6$), 26.66 ($C_4 + C_5$), 24.53 (CH_3 of acetamido). *Anal.*; Calc. for $C_{11}H_{19}N_3O_5Pt$: C, 28.20; H, 4.08; N, 8.97%. Found: C, 28.26; H, 4.38; N, 9.03%.

Preparation of R,R-FMP, 2


This was prepared as for 4 and recrystallized from water-ethanol in 65% yield. Decomp. point 214°C ; IR 3063–3289 (NH), 2950, 2922 (CH, CH_2), 1683, 1563 (amide C=O), 1640 (coordinated carboxyl C=O), 1387 (C–O). ^1H NMR (DMSO- d_6): δ 8.03 (d, 1H, $-(C=O)NH$, $J_{NH-CH} = 8.28$ Hz), 8.00 (s, 1H, $HC(=O)$), 6.08 (dd, 2H, NH_2), 5.62 (d, 1H, CH, $J_{NH-CH} = 8.28$ Hz), 5.41 (dist. q, 2H, NH_2), 2.08 (bt, 2H, $H_1 + H_2$), [1.81 (bd, 2H) and 1.23 (m, 2H), ($H_3 + H_6$)], [1.45 (bd, 2H) and 1.00 (m, 2H), ($H_4 + H_5$)]. ^{13}C NMR (D_2O): δ 65.31 (C_2), 65.07 (C_1), 60.46 (C_2), 34.43 ($C_3 + C_6$), 26.62 ($C_4 + C_5$). *Anal.*; Calc. for $C_{10}N_{17}N_3O_5Pt$: C, 26.43; H, 3.77; N, 9.24%. Found: C, 26.21; H, 3.72; N, 9.03%.

TABLE I

Selected IR bands (cm^{-1}) and molar conductances for the platinum(II) complexes

Compound	NH	Acetyl (C=O)	Amide (C=O)	Asym (C=O)	Sym (C=O)	$\text{Ohm}^{-1}/\text{cm}^{-2}/\text{M}^{-1}$
<i>R,R</i> -AMP, 1	3200–3240		1617	1645	1400	8
<i>R,R</i> -FMP, 2	3063–3289		1683	1640	1387	11
<i>R,R</i> -AG-AMP, 3	3213	1744	1666	1644	1375	7
<i>R,R</i> -G-AMP, 4	3100–3300		1672	1651	1388	8

TABLE II

 ^1H NMR data for the platinum(II) complexes

Compound	$\text{C}_{1,2}\text{H}$	$\text{C}_{3,6}\text{H}$	$\text{C}_{4,5}\text{H}$	NH_2	NH C_2H
Acetamidomalonic Acid					8.54(d) 4.88(d) ($J_{\text{NH}-\text{CH}} = 7.95$)
DAC- PtI_2^a	2.55(bs)	2.15(bd) 1.55(m,4H)	1.15(m)	5.6(ud), 4.95(ut)	
<i>R,R</i> -AMP ^b , 1	2.08(bs)	1.82(bd) 1.20(m)	1.45(bd) 1.02(m)	6.03(dd), 5.38(bt)	7.65(d) 5.57(d) ($J_{\text{NH}-\text{CH}} = 8.18$)
<i>R,R</i> -FMP ^b , 2	2.08(bt)	1.81(bd) 1.23(m)	1.45(bd) 1.00(m)	6.08(dd), 5.41(dsq)	8.03(d) 5.62(d) ($J_{\text{NH}-\text{CH}} = 8.28$)
<i>R,R</i> -AG-AMP ^a , 3	2.45(bs)	2.09(m) 1.45(m)	1.55(bd) 1.10(bt)	6.21(dd), 5.39(m)	7.41(d) 5.51(d) ($J_{\text{NH}-\text{CH}} = 7.35$)
<i>R,R</i> -G-AMP ^a , 4	2.63(bs)	2.20(ud) 1.61(m)	1.70(ud) 1.31(m)	6.38(dd), 5.62(m)	8.04(d) 5.76(d) ($J_{\text{NH}-\text{CH}} = 7.31$)

^aDMF- d_7 , (relative to TMS). ^bDMSO- d_6 (2.50); d: doublet; bd: broad doublet; t: triplet; bt: broad triplet; ud: unresolved doublet; ut: unresolved triplet; m: multiplet; dsq: distorted quartet.

Preparation of *R,R*-AG-AMP, 3:


This was prepared as described for 4 and recrystallized from methanol-ether in 55% yield. Decomp. point 189 °C; IR 3213 (NH), 2936, 2865 (CH, CH_2), 1744, 1666 (acetyl and amide C=O), 1644 (coordinated carboxyl C=O), 1375 (C–O). ^1H NMR (DMF- d_7): δ 7.41 (d, 1H, C(=O)NH, $J_{\text{NH}-\text{CH}} = 7.35$), 6.21 (dd, 2H, NH_2), 5.74 (t, 1H, sugar), 5.51–5.39 (mm, 4H, $\text{NH}_2 + \text{CH}$ ($J_{\text{NH}-\text{CH}} = 7.35$) + sugar), 5.12 (q, 1H, sugar), 4.42 (dd, 1H, sugar), 4.23 (dd, 1H, sugar), 2.45 (bs, 2H, $\text{H}_1 + \text{H}_2$), 2.25 (s, 3H, $\text{CH}_3-\text{C}(=\text{O})$), 2.09 (3xs + m, 11H, $3x\text{CH}_3-\text{C}(=\text{O}) + \text{H}_3$ or H_6), [1.55 (bd, 2H) and 1.10 (bt, 2H), ($\text{H}_4 + \text{H}_5$), 1.45 (m, 2H, H_3 or H_6). ^{13}C NMR (DMF- d_7): δ 172.11,

171.65, 170.89, 170.49, 170.29, 170.08, 165.68 (acetyls + amide + carboxylate C(=O)), 73.01, 70.57, and 69.76 (sugar), 63.64 (C₂), 63.13 (C₁), 61.87 (sugar), 59.57 (C₂), 32.53 (C₃ + C₆), 24.99 (C₄ + C₅), 20.67, 20.58 (acetyls). *Anal.*; Calc. for: C₂₅H₃₇N₃O₁₅Pt·H₂O: C, 36.06; H, 4.72; N, 5.05%. Found: C, 36.86; H, 4.60; N, 5.04%.

RESULTS AND DISCUSSION

In view of the difficulties in purifying platinum complexes,¹²⁻¹⁴ the purity of each complex was determined by its elemental analysis and HPLC (>98% by HPLC). Analytical data for the platinum(II) complexes (see Experimental) are in good agreement with the chemical formulation of the proposed structure I. Molar conductivities were measured to assess the electrolytic nature of the complexes in water (Table I). The molar conductances of compounds 1-4 immediately after dissolution in distilled deionized water at room temperature are below 11 cm² ohm⁻¹ mol⁻¹, suggesting a neutral 1:1 adduct for all of the complexes.¹⁵

TABLE III
¹³C and ¹⁹⁵Pt NMR data for the platinum(II) complexes and their intermediates.



Compound	C ₁	C ₂	C _{3,6}	C _{4,5}	Carboxylate and Amide (C=O)	¹⁹⁵ Pt
Gluconylaminomalonic acid ^a					165.90, 161.15 161.01	
Gluconylaminomalonic acid ^b					173.17, 168.81	
Barium gluconylaminomalonate ^a					175.05, 174.95 174.37	
<i>R,R</i> -DAC-PtI ₂ ^a	64.52		32.40	25.21		
<i>R,R</i> -DAC-PtSO ₄ ^a	65.97		32.20 ^c	26.56 ^c		
<i>R,R</i> -DAC-Pt(OH) ₂ ^a	65.5 ^c		35.09	26.68		
<i>R,R</i> -AMP ^a , 1	65.41	65.56	34.57 34.49	26.66	176.73, 176.48	-1947.36 ^d
<i>R,R</i> -FMP ^a , 2	65.07	65.31	34.43	26.62		-1951.31 ^d
<i>R,R</i> -AG-AMP ^b , 3	63.13	63.64	32.53	24.99	172.11, 171.65 170.89, 170.49 170.29, 170.08 165.68	-1951.3 ^d
<i>R,R</i> -G-AMP ^b , 4	62.20	62.50	31.49	23.95	172.10, 171.54 171.18	-1946 ^b

^aD₂O. ^bDMF-*d*₇. ^ctwo overlapping signals. ^dDMSO-*d*₆.

Inspection of the IR spectra of compounds 1-4 (Table I) shows strong bands around 1651 and 1375 cm⁻¹ assignable to the asymmetric and symmetric carbonyl stretching of the coordinated carboxylic groups.¹⁶ The carbonyl stretching of the

acetyl group in *R,R*-AG-AMP shows a strong absorption at 1744 cm^{-1} and the amide carbonyl stretching frequency for the complexes appears in the range $1617\text{--}1683\text{ cm}^{-1}$.




FIGURE 1 $^1\text{H}\text{--}^1\text{H}$ Homonuclear chemical-shift correlated (COSY) of *R,R*-G-AMP, 4.

Selected ^1H and ^{13}C NMR chemical shifts for each of the platinum compounds 1–4 are tabulated in Tables II and III, respectively. Complete chemical shift assignments for each complex are listed in the experimental section. 2D-COSY- $\{^1\text{H}\text{--}^1\text{H}\}$ (Figure 2) and 2D-HETCOSY- $\{^1\text{H}\text{--}^{13}\text{C}\}$ (Figure 3) of *R,R*-G-AMP, as a complex representative, were carried out to facilitate the chemical shift assignments.

All of the complexes exhibit two sets of doublets around 7.65–8.04 and 5.51–5.76 ppm due to the amide-NH and the methyne proton, respectively. The methyne proton of the malonate derivatives in the platinum complexes are shifted downfield as compared to the corresponding proton in the free malonic acid derivatives. For example, the methyne proton in *R,R*-AMP appears at 5.57 ppm, while the same resonance in the free acetamidomalonic acid is observed at 4.88 ppm. This downfield chemical shift is due to the coordination of acetamidomalonic acid to platinum through its two carboxylate oxygens. The resonance peaks around 6.38–6.03 and 5.62–5.38 ppm, in the spectra of 1–4, are exchangeable with D₂O and are assigned to the chelated amino groups. The broad singlets at 6.15, 5.03, 4.79, 4.66, and 4.53 ppm, in the spectrum of *R,R*-G-AMP, were also exchangeable with D₂O and they are assigned to the gluconyl hydroxyl groups.




FIGURE 2 ¹H-¹³C Heteronuclear chemical-shift correlated (HETCOSY) of *R,R*-G-AMP, 4.

¹³C NMR of 1–4 and selected reference platinum complexes were carried out in D₂O, DMF-*d*₇, or DMSO-*d*₆ (Table III and Experimental Section). The number of carbon signals observed for each compound corresponds to that expected for a monomeric single platinum complex. The MS(FAB) spectrum of *R,R*-G-AMP shows 5 peaks at *m/z* values of 604(¹⁹⁴Pt), 605(¹⁹⁵Pt), 606(¹⁹⁶Pt), 607(¹⁹⁷Pt), and 608(¹⁹⁷Pt), a pattern expected for naturally abundant Pt isotopes, further supporting the monomeric nature of these complexes. In contrast to results reported by Gandolfi *et al.*,¹⁷ where doubling of the number of ¹³C signals for the cyclohexane ring

carbons of aminomalonato-DAC-platinum(II) was observed as compared to the free DACH, the ^1H (Table II) and ^{13}C NMR (Table III) spectra of compounds 1–4 show no evidence for the presence of more than one species.

Finally, since the chemical shifts of ^{195}Pt are very sensitive to the donor ligand,¹⁸ ^{195}Pt NMR of structures 1–4 was carried out to elucidate the molecular environment of the platinum metal. A single broad peak was observed in the –1946 to –1951 ppm range for each of the complexes (Table III), a chemical shift region characteristic of an (*O,O*)-Pt system,¹⁹ therefore ruling out chelation of the amide nitrogens to the platinum metal. Appleton *et al.*¹⁹ reported the ^{195}Pt peak at –2026 ppm for (*N,O*)-Pt coordination in the reaction of *N*-acetyl glycine with diamminediaqua-platinum(II) cation, where glycine binds to the platinum metal through its amine nitrogen and carboxylate oxygen. The broadening of the ^{195}Pt signal is not surprising when one or more ^{14}N atoms are bonded to platinum. Partial decoupling of ^{195}Pt due to rapid quadrupole-induced relaxation of ^{14}N broadens the platinum signals.²⁰ These compounds are currently undergoing preclinical evaluation as potential antitumor agents.

ACKNOWLEDGEMENT

This investigation was supported by US Bioscience.

REFERENCES

1. J.R. Durant, in "Cisplatin, Current Status and New Development", A.W. Prestayko, S.T. Crooke and S.K. Carter (eds.), (Academic Press, New York, 1980), pp. 317–321.
2. P.J. Loehrer and L.H. Einhorn, *Ann. Intern. Med.*, **100**, 704 (1984).
3. A.W. Prestayko, W.T. Bradner, J.B. Huftalen, W.C. Rose, J.E. Schurig, M.J. Clear, P.C. Hydes and S.T. Crooke, *Cancer Treatment Review.*, **63**, 1503 (1979).
4. J.B. Vermorken and H.M. Pinedo, *Neth. J. Med.*, **25**, 270 (1982).
5. J.M. Ward, M.E. Grabin, E. Berlin and D.M. Young, *Cancer Research*, **37**, 1238 (1977).
6. M.F. Pera and H.C. Harder, *Cancer Research*, **39**, 1279 (1979).
7. M. Noji, K. Suzuki, T. Tashiro, M. Suzuki, K.I. Harada, K. Masuda and Y. Kidani, *Chem. Pharm. Bull.*, **35**, 221 (1987).
8. M.P. Hacker, E.B. Douple and I.H. Krakoff (eds.), "Platinum Coordination Complexes in Cancer Chemotherapy", (Martinus Nijhoff, Boston, 1984).
9. A.R. Khokhar and I.H. Krakoff, *Inorg. Chim. Acta*, **108**, 63 (1985).
10. J.H. Burchenal, K. Kalaher, K. Dew and L. Lokys, *Cancer Treat. Rep.*, **63**, 1493 (1979).
11. M.E. Howe-Grant and S.J. Lippard, in Sigel (ed.), "Metal Ions in Biological Systems", Vol. 11, (Marcel Dekker, New York, 1980), p. 63.
12. R.J. Speer, H. Ridgway, L.M. Hall, D.P. Stewart, K.E. Howe, D.Z. Lieberman, A.D. Newman and J.M. Hill, *Cancer Treat. Rep.*, **59**, 629 (1975).
13. J.D. Roberts, W.J. Schmidt, W.P. Tong and M.P. Hacker, *Inorg. Chim. Acta*, **153**, 123 (1988).
14. J.D. Hoeschele, N. Farrell, W.R. Turner and C.D. Rithner, *Inorg. Chem.*, **27**, 4106 (1988).
15. R.J. Angelici, "Synthesis and Techniques in Inorganic Chemistry", 2nd ed., (Saunders, Philadelphia, 1977), p. 18.
16. K. Nakamoto, "Infrared Spectra of Inorganic Solids and Coordination Compounds", 3rd ed., (Wiley, New York, 1978), p. 308.
17. O. Gandolfi, H.C. Apfelbaum and J. Blum, *Inorg. Chim. Acta*, **135**, 27 (1987).
18. P.S. Pregosin, *Coord. Chem. Rev.*, **44**, 247 (1982).
19. (a) T.G. Appleton, J.R. Hall and P.D. Prenzler, *Inorg. Chem.*, **28**, 815 (1989); (b) T.G. Appleton, J.R. Hall and S.F. Ralph, *Inorg. Chem.*, **24**, 4685 (1985).
20. M.I. Ismail, J.S. Kerrison and P.J. Sadler, *Polyhedron*, **1**, 57 (1982).